Teva partners with Samsung Bioepis to commercialize two U.S. biosimilars
TEVA•Teva agreed to commercialize two FDA-approved immunology biosimilars in the U.S. Rights to ETICOVO are expected to transfer by year-end 2026, and rights to infliximab-abda in the third quarter of 2027.
1. Licensing agreement
Teva entered a licensing and commercialization agreement with Samsung Bioepis for U.S. rights to two FDA-approved immunology biosimilars. ETICOVO rights are expected to transfer at closing by year-end 2026, while rights to infliximab-abda are expected to transfer in the third quarter of 2027. Samsung Bioepis will retain regulatory oversight and manufacturing responsibility for both products. Payments include an upfront payment over three years, potential launch and sales milestones, and shared commercialization profits.
